Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Superagonism at the Human Somatostatin Receptor Subtype 4

Mia Engström, Jussi Tomperi, Kamel El-Darwish, Mikaela Åhman, Juha-Matti Savola and Siegfried Wurster
Journal of Pharmacology and Experimental Therapeutics January 2005, 312 (1) 332-338; DOI: https://doi.org/10.1124/jpet.104.075531
Mia Engström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jussi Tomperi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamel El-Darwish
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikaela Åhman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juha-Matti Savola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siegfried Wurster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We have discovered a novel compound, J-2156 [(1′S, 2S)-4-amino-N-(1′-carbamoyl-2′-phenylethyl)-2-(4″-methyl-1″-naphthalenesulfonylamino)butanamide], that belongs to a new class of somatostatin receptor ligands. J-2156 binds with nanomolar affinity to the human somatostatin receptor subtype 4 and is over 400-fold subtype-selective against the other somatostatin receptors. When evaluated in a [35S]guanosine-5′-O-(3-thio) triphosphate binding assay, J-2156 elicited a response 2 to 3 times as large as that of somatostatin-28 and somatostatin-14. That somatostatin-14 is clearly not a maximally efficacious agonist could be verified by demonstrating that it displays the typical behavior of a partial agonist when tested against J-2156. Increasing concentrations of somatostatin-14 cause a concentration-dependent rightward shift of the dose-response curves for J-2156, without affecting its maximal response. This lack of reduction of the maximal response and the fact that the superior efficacy of J-2156 is detected in membranes argue against desensitization and internalization as possible explanations for the superior efficacy of J-2156. More likely is that somatostatin-14 and J-2156 stabilize distinct receptor conformations that differ in their ability to interact with G-proteins. In a cyclic AMP assay, J-2156, somatostatin-28, and somatostatin-14 all act as full agonists. However, this outcome is most likely due to the presence of a receptor reserve in the cyclic AMP assay since there is a large gain of apparent potency in the cyclic AMP assay and the gain is larger for J-2156 than for somatostatin. We conclude that the endogenous ligands somatostatin-14 and somatostatin-28 do not define maximal agonism on the human somatostatin receptor subtype 4 and that J-2156 represents a so-called superagonist.

Footnotes

  • This work was supported by the National Technology Agency of Finland (Tekes).

  • doi:10.1124/jpet.104.075531.

  • ABBREVIATIONS: SRIF, somatotropin release-inhibiting factor; GPCR, G-protein-coupled receptor; sst1-5, somatostatin receptor subtypes 1 through 5; h sst1-5, human sst1-5; J-2156, (1′S, 2S)-4-amino-N-(1′-carbamoyl-2′-phenylethyl)-2-(4″-methyl-1″-naphthalenesulfonylamino)butanamide; DMF, N,N-dimethylformamide; DCM, dichloromethane; Fmoc, 9-fluorenylmethoxycarbonyl; Boc, tert-butyloxycarbonyl; CHO, Chinese hamster ovary; 125I-LTT-SRIF-28, (125I-Tyr)-[Leu8,DTrp22]-somatostatin-28; [35S]GTPγS, [35S]guanosine-5′-O-(3-thio)triphosphate.

    • Received August 2, 2004.
    • Accepted August 27, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 312 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 312, Issue 1
1 Jan 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Superagonism at the Human Somatostatin Receptor Subtype 4
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Superagonism at the Human Somatostatin Receptor Subtype 4

Mia Engström, Jussi Tomperi, Kamel El-Darwish, Mikaela Åhman, Juha-Matti Savola and Siegfried Wurster
Journal of Pharmacology and Experimental Therapeutics January 1, 2005, 312 (1) 332-338; DOI: https://doi.org/10.1124/jpet.104.075531

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

Superagonism at the Human Somatostatin Receptor Subtype 4

Mia Engström, Jussi Tomperi, Kamel El-Darwish, Mikaela Åhman, Juha-Matti Savola and Siegfried Wurster
Journal of Pharmacology and Experimental Therapeutics January 1, 2005, 312 (1) 332-338; DOI: https://doi.org/10.1124/jpet.104.075531
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Chlorogenic Acid Inhibits Breast Cancer Metastasis
  • SNAP25 and mGluRs Control Pathological Tau Release
  • N-Stearoylethanolamine Inhibits Platelet Reactivity
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics